Clinical Trial Update: Arsenic Trioxide in Treating Patients With Refractory or Recurrent Acute Promyelocytic Leukemia [Phase 1, Phase 2]

View source ↗

Summary

A phase 1/2 clinical trial evaluated arsenic trioxide for patients with refractory or recurrent acute promyelocytic leukemia; the study is reported as completed…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Promyelocytic Leukemia

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Leukemia | Phase 1, Phase 2 | Status: COMPLETED